* Kiora Pharmaceuticals Inc reported a quarterly adjusted loss of 47 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-1.76. The mean expectation of three analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -48 cents to -36 cents per share.
* Reported revenue was zero; analysts expected zero.
* Kiora Pharmaceuticals Inc's reported EPS for the quarter was a loss of 47 cents.
* The company reported a quarterly loss of $2.27 million.
* Kiora Pharmaceuticals Inc shares had risen by 14.9% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 99.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $3.00 This summary was machine generated from LSEG data March 25 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.42 -0.47 Missed
Sep. 30 2023 -0.35 -0.89 Missed
Jun. 30 2023 -1.07 -0.79 Beat
Mar. 31 2023 -1.68 -1.00 Beat
Comments